Ignite Creation Date:
2024-05-05 @ 9:06 PM
Last Modification Date:
2024-10-26 @ 9:59 AM
Study NCT ID:
NCT00819546
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-01-23
First Post:
2009-01-08
Brief Title:
RAD001 in Combination With PKC412 in Patients With Relapsed Refractory or Poor Prognosis AML or MDS
Sponsor:
Richard Stone MD
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
08-269
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Richard Stone MD
Lead Sponsor Class:
OTHER
Responsible Party:
Richard Stone MD
Responsible Party Title:
Professor of Medicine
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Novartis | INDUSTRY |
| Beth Israel Deaconess Medical Center | OTHER |
| Massachusetts General Hospital | OTHER |
| Brigham and Womens Hospital | OTHER |